Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07424872

Project VERANDA: Requirement Analysis Survey

Between 0.6% and 22.2% of the global adult male population has a sexual interest in children (SIIC), depending on evaluation methods [1]. SIIC constitutes a major risk factor for child sexual abuse (CSA) and viewing of child sexual abuse material (CSAM). The true rates of CSA offences cannot be estimated, but self-report studies find 30 times higher rates of child-reported CSA compared to reports from child protection services or police.

Engagement in therapy is a protective factor against the risk of child sexual abuse and can lead to reductions in CSAM consumption and severity. Anticipated negative therapist behaviour is associated with less willingness to seek treatment. The fear of being reported by the therapist discourages participation in therapy, a concern complicated by mandatory reporting laws in some countries. Negative attitudes towards ISIC are high, and SIIC may be the most stigmatised trait globally.

Identifying barriers to treatment for ISIC, and of measures to overcome them, is important to increase therapy engagement, with the goal to improve wellbeing, reduce CSAM consumption, and reduce the risk of CSA offences. Patient anonymity during therapy may play an important role in increasing disclosure of stigmatised traits. It remains unclear whether anonymous therapy addresses patient treatment anxieties and therefore increases the comfort or willingness to engage in therapy. To address this research gap, we conduct an anonymous online survey with ISIC to answer the following questions:

RQ1. Can online therapy preferences be identified for minor-attacted individuals and for their therapists?

RQ2. Are there individual factors that predict stigmatized individuals' online therapy preferences? (E.g. Trust, Self-Stigma)

RQ3. Are there differences between the different stigmatized groups', therapists, and general populations' online therapy preferences?

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Charité - Universitätsmedizin Berlin

Berlin, State of Berlin, 10117, Germany

Location status: Recruiting

Location contact

Luke Flanagan

CONTACT

[email protected]

+4916092338142

About this study

Participants will receive a study information that describes the aim of the project and a brief overview of data anonymization procedures. This study information is in simple English for comprehesability. Participants will have the option to access more detailed study information, explaining that privacy protections are implemented; tracking technologies are disabled; data will be encrypted and stored on Charité - Universitätsmedizin Berlin servers in compliance with the EU General Data Protection Regulation; and that anonymized data might be shared with academic research institutes within the project consortium. It is also stated that data could be stored for up to three years and that access will be restricted to project members only. To ensure accessibility and comprehensibility for diverse populations, the study information was additionally provided in an easy-to-understand language version. Participants are required to provide informed consent (collected via checkbox without personally-linkable ID) before participation. The questionnaire is available in both German and English.

Pilot testing was conducted prior to the main data collection, involving researchers and general members of the public who are not experts in the topic of the study. The pilot study evaluated the comprehensibility, sensitivity, clarity, and overall acceptability of the questionnaire items. In addition, technical functionality and user experience were informally tested across different individuals and devices.

This study was approved by the Institutional Ethics Committee of Charité - Universitätsmedizin Berlin (ID EA4_187_24).

The Charité data protection officewas consulted prior to the start of this study to ensure compliance with applicable data protection regulations, and their advise was implemented.

An instance of the survey tool SoSci Survey was hosted on Charité servers. Server-side IP logging disabled are disabled. Within SoSci Survey, cookies and IP-tracking are disabled, and a "Leave and delete my data" button is available for participants prior to final submission of their data. Participants are instructed not to provide any identifiable information either within the Survey or by email to the study team.

For preservation of anonymity, consent will be collected only via checkbox, and no records of individual identity were stored. To limit the identifiability of the data through data linkage, demographic information is limited to high-level information rather than specific information, such as country of residence rather than nationality, and age range rather than precise age. We also provide guidelines to participants about how to increase their privacy on the project website (https://project-veranda.github.io/VERANDA/news/How_to_protect_your_identity/) online. To the best of our efforts, this survey will be conducted anonymously.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Belonging to one of the target groups.
  • Otherwise, for general members of the public, none.

Exclusion criteria

  • Younger than 18

Treatment and study plan

Primary outcomes

  1. Preferences of design features

    Time frame: May 2025 - May 2026

    RQ1.1 Can preferences of design features for an online therapy tool be identified for minor-attacted individuals and for their therapists?

    RQ3.4 Are there differences between the different groups in the preferred choice of consultation technology?

    Preferences of design features for an online therapy tool: 7-point Likert scale.

Secondary outcomes

  1. Preferred choice of consultation method

    Time frame: May 2025 - May 2026

    RQ1.2 Can the preferred choice of consultation method be identified?

    RQ2.3 Does self-stigma, treatment anxiety or trust influence the preferred choice of consultation method?

    RQ3.3 Are there differences between the different groups in the preferred choice of consultation method?

    In-person or anonymously online; Individual therapy or group therapy: 7-point bi-directional Likert scale. Responses will be dichotomized into two categories (e.g., "prefer 1-to-1" vs. "prefer group therapy") with neutral responses excluded from the analysis. This results in binary outcome variables.

Other outcomes

  1. Preferred choice of consultation technology

    Time frame: May 2025 - May 2026

    RQ2.4 Does self-stigma, treatment anxiety or trust influence the preferred choice of consultation technology?

    (text-only, audio-only, or video and audio; Smartphone or laptop; App or browser extension): 7-point bi-directional Likert scale (e.g., preference for laptop vs. smartphone). Responses will be dichotomized into two categories (e.g., "prefer laptop" vs. "prefer smartphone"), with neutral responses excluded from the analysis. This results in binary outcome variables.

  2. Preference of having PETs for an online therapy tool

    Time frame: May 2025 - May 2026

    RQ2.2 Do preferences of having PETs for an online therapy tool vary based on self-stigma, treatment anxiety, or trust?

    RQ3.2 Do preferences of having PETs for an online therapy tool vary between different groups?

    Preferences for using various privacy-enhancing technologies (PETs) in online therapy will be measured with multiple items on a 7-point Likert scale. An exploratory factor analysis (EFA) will be conducted to examine the underlying structure. Based on the factor solution, items loading on a common factor will be combined to create a composite score.

  3. Willingness to engage in therapy

    Time frame: May 2025 - May 2026

    RQ2.1.1 Does self-stigma, treatment anxiety, or trust influence willingness to engage in non-anonymous online therapy?

    RQ2.1.2 Does self-stigma, treatment anxiety, or trust influence willingness to engage in anonymous online therapy?

    RQ2.1.3 Does self-stigma, treatment anxiety, or trust influence willingness to engage in in-person therapy?

    RQ3.1.1 Are there differences between the different groups in willingness to engage in non-anonymous online therapy?

    RQ3.1.2 Are there differences between the different groups in willingness to engage in anonymous online therapy?

    RQ3.1.3 Are there differences between the different groups in willingness to engage in-person therapy?

    3-Point scale that will be categorized into two binary categories, willingness to engage or unwillingness. Willingness to engage in specific therapy methods (anonymous online, non-anonymous online, in-person) is measured on a 3-point Likert Scale.

  4. Communication cue importance for effective therapy

    Time frame: May 2025 - May 2026

    7-point Likert Scale

    Audio cues (E.g. Accent, slang)

    Visual cues (E.g. Manner of dress, body language)

    Written cues (E.g. Slang, Specific word choice)

  5. Treatment-Related Anxieties

    Time frame: May 2025 - May 2026

    What fears and concerns do potential users have regarding participating in (digital) therapy? (groups: stigmatized groups, therapists, general public; descriptive statistics: means, SD). We look at individual measures on the Treatment Anxieties Questionnaire, rather than a sum score, with the addition of a question relating to concerns of being prosecuted by law enforcement.

  6. Are there mediums or media sources that an average prospective patient is more willing to trust?

    Time frame: May 2025 - May 2026

    We will report descriptive statistics (mean, standard deviation) for each of the mediums or media and examine for statistical difference between them using a 1-way Kruskal-Wallis test. If statistical differences are found, we will further examine for significant differences with a Matt-Whitney U-Test for pairwise comparison.

    Are there other factors that influence a prospective patient's decision to download and use a healthcare tool?

    Responses given in the free text box will be coded by theme or avenue and reported descriptively.

  7. Which cues are important to be preserved from anonymization (or otherwise sufficiently accurately conveyed) for a therapist to be able to provide therapy?

    Time frame: May 2025 - May 2026

    All cues will be measured with descriptive statistics (mean, standard deviation). This will only be measured for therapists, prospective patients were not asked this question.

  8. Level of acceptable body-language and facial expression communication

    Time frame: May 2025 - May 2026

    Is there a preference in terms of body-language and facial expression display, either preferring no expression to be displayed, only facial expressions, or also body language?

  9. Browser Extension or Independent App

    Time frame: May 2025 - May 2026

    Is there a preference between the toolset being available as a browser extension or as an app?

  10. What are therapists' opinions regarding anonymization and anonymity in (psycho)therapy?

    Time frame: May 2025 - May 2026

    6.1 - 6.2: These will be reported using descriptive statistics (mean, standard deviation) for therapists data only.

    6.3: We will conduct an Explorative Factor Analysis to generate factors like e.g. the anonymity feature preference score for both MAP and MAP therapists. Then, we will use Mann-Whitney U-Test to test for significant differences.

Study contacts

Contact information is provided by the study sponsor or research team.

Prof. Dr.-Ing Poikela

CONTACT

[email protected]

30 450 528 786 ext. +49

Sponsors and collaborators

Lead sponsor

Berlin Institute of Health @ Charité

Other

Collaborators

  • Charite University, Berlin, Germany
  • Deutsches Forschungszentrum für Künstliche Intelligenz GmbH (DFKI)
  • Fraunhofer Institute for Applied and Integrated Security AISEC
  • Technische Universität Berlin

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Feb 20, 2026
Registry last updated
Mar 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.